title: Biodegradable PLGA-Based Drug Delivery Systems for Modulating Ocular Surface Disease under Experimental Murine Dry Eye.
abstract: Continuous drug delivery to the ocular surface remains difficult due to the rapid tear clearance of topically applied agents. The purpose of this study was to evaluate biodegradable and biocompatible drug delivery systems on the ocular surface using poly-lactic-co-glycolic acid (PLGA) based polymers.
  
  
  
  Fluorescein-labeled albumin and doxycycline were individually encapsulated into a PLGA-based matrix using a water-oil-water double emulsion method. The drug elution rates for various microspheres were evaluated spectrofluorometrically. Particle size was measured using image analysis software. Subconjunctival injections of PLGA microspheres were used to evaluate safety and inflammatory response to the polymer in the murine model. Efficacy of the drug delivery system was evaluated by a single subconjunctival injection of PLGA-doxycycline (a broad metalloproteinase inhibitor) prior to induction of desiccating stress (DS) model in C57BL/6 mice for 5 days.
  
  
  
  PLGA-based microspheres successfully elute encapsulated drugs of interest continuously over controlled periods of time. Mean PLGA-based microparticle diameter was 4.6 μm±1.54 μm. Drug elution rates and delivery times were easily modifiable by altering polymers and synthesis parameters.In vitrostudies demonstrate successful continuous elution of encapsulated drugs for at least 2 weeks.In vivotesting of PLGA-doxycycline was efficacious in preventing DS-induced corneal barrier disruption with desiccating stress, similarly to topically applied doxycycline.
  
  
  
  PLGA-based drug delivery systems are safe and non-inflammatory. They can be successfully used to treat ocular surface and corneal diseases by continuously delivering biopharmaceuticals of interest.
authors.affiliation: Ocular Surface Center, Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chang
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McClellan
authors.forename: William J
authors.initials: WJ
authors.lastname: Farley
authors.forename: De-Quan
authors.initials: DQ
authors.lastname: Li
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Pflugfelder
authors.forename: Cintia S
authors.initials: CS
authors.lastname: De Paiva
keywords: Desiccating stress; Doxycycline; PLGA
references.citation: J Control Release. 2007 May 14;119(1):59-68
references.pmid: 17331611
references.citation: Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2847-56
references.pmid: 16799024
references.citation: Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3493-504
references.pmid: 8056525
references.citation: J Pharm Sci. 2006 Nov;95(11):2393-405
references.pmid: 16886193
references.citation: Pharm Dev Technol. 2011 Feb;16(1):29-35
references.pmid: 20038266
references.citation: J Control Release. 2011 May 10;151(3):286-94
references.pmid: 21241752
references.citation: Arch Ophthalmol. 1987 Feb;105(2):268-71
references.pmid: 3813962
references.citation: J Pak Med Assoc. 1990 Mar;40(3):66-7
references.pmid: 2113958
references.citation: Mucosal Immunol. 2009 May;2(3):243-53
references.pmid: 19242409
references.citation: Diabetes. 2009 Aug;58(8):1902-13
references.pmid: 19491211
references.citation: Int J Pharm. 2007 Apr 4;334(1-2):137-48
references.pmid: 17196348
references.citation: Adv Drug Deliv Rev. 1997 Oct 13;28(1):25-42
references.pmid: 10837563
references.citation: Am J Ophthalmol. 2004 Sep;138(3):444-57
references.pmid: 15364229
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002898
references.pmid: 17253484
references.citation: Pharm Res. 1991 Jun;8(6):713-20
references.pmid: 2062800
references.citation: Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3203-9
references.pmid: 19255163
references.citation: Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4302-11
references.pmid: 15557436
references.citation: J Microencapsul. 2009 Feb;26(1):18-26
references.pmid: 18465288
references.citation: Am J Pathol. 2005 Jan;166(1):61-71
references.pmid: 15632000
references.citation: Ophthalmology. 1997 Nov;104(11):1863-7
references.pmid: 9373118
references.citation: J Biomed Mater Res. 1997 Jun 15;35(4):525-30
references.pmid: 9189830
references.citation: Am J Public Health. 1993 May;83(5):711-6
references.pmid: 8484454
references.citation: Exp Eye Res. 2006 Sep;83(3):526-35
references.pmid: 16643899
references.citation: Invest Ophthalmol Vis Sci. 2002 Mar;43(3):632-8
references.pmid: 11867577
references.citation: Ophthalmology. 1998 Jun;105(6):1114-9
references.pmid: 9627665
references.citation: Am J Ophthalmol. 2001 Jul;132(1):8-13
references.pmid: 11438047
references.citation: Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24
references.pmid: 10837562